Merrithew & Thorsten’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-129
Closed -$40K – 56
2026
Q2
$40K Hold
129
– – 0.03% 50
2026
Q1
$25K Hold
129
– – 0.02% 58
2025
Q4
$24K Buy
+129
New +$24.8K 0.03% 56

Other funds holding LGND

Merrithew & Thorsten's LGND Position: Q3 2026 in Review

Merrithew & Thorsten sold out of Ligand Pharmaceuticals (LGND) in Q3 2026, closing a stake of 129 shares — an estimated $40K sold.

Merrithew & Thorsten first reported a position in LGND in Q4 2025 and held it in 3 quarters. The position peaked at $40K in Q2 2026. 348 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

  • Merrithew & Thorsten reported no remaining Ligand Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Merrithew & Thorsten sold 129 Ligand Pharmaceuticals shares in Q3 2026, an estimated $40K.
  • Merrithew & Thorsten first reported a position in Ligand Pharmaceuticals in Q4 2025 and held it in 3 quarters.
  • Merrithew & Thorsten's Ligand Pharmaceuticals position peaked at $40K in Q2 2026.
  • 348 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on Merrithew & Thorsten's 13F filing for Q3 2026, filed 6 Nov 2026.